Chronic hepatitis B. (Q34002160)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Chronic hepatitis B.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Chronic hepatitis B. (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

chronic hepatitis

1 reference

based on heuristic

inferred from title

author name string

Anna S F Lok

1

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Brian J McMahon

2

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

language of work or name

0 references

publication date

1 February 2007

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

45

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

507-539

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Incidence of hepatitis B virus infections in preschool children in Taiwan.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

21 January 2018

Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

21 January 2018

Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults

2 references

https://api.crossref.org/works/10.1002%2FHEP.21513

21 January 2018

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical aspects of the interactions between human immunodeficiency virus and the hepatotropic viruses

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

21 January 2018

The effect of concurrent human immunodeficiency virus infection on chronic hepatitis B: a study of 150 homosexual men.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

21 January 2018

Hepatitis B virus genotypes: do they play a role in the outcome of HBV infection?

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

21 January 2018

Seroconversion from Hepatitis B e Antigen to Antibody in Chronic Type B Hepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

21 January 2018

Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

21 January 2018

Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

21 January 2018

Hepatitis B virus-associated coinfection and superinfection with delta agent: indistinguishable disease with different outcome

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

21 January 2018

Influence of hepatitis delta virus infection on progression to cirrhosis in chronic hepatitis type B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

21 January 2018

Updated definitions of healthy ranges for serum alanine aminotransferase levels

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

21 January 2018

Interferon-alpha therapy for chronic hepatitis B in children: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

21 January 2018

A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

21 January 2018

A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

21 January 2018

Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

21 January 2018

A controlled trial of interferon with or without prednisone priming for chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

21 January 2018

Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

21 January 2018

American Gastroenterological Association policy statement on the use of medical practice guidelines by managed care organizations and insurance carriers

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of hepatitis B: 2000--summary of a workshop

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis B virus. The major etiology of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidemiology of Hepatocellular Carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of the hepatitis B virus in the liver transplantation setting: a European and an American perspective

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidemiology and natural history of hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Strategies to prevent and control hepatitis B and C virus infections: a global perspective

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival of hepatitis B virus after drying and storage for one week

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Age- and sex-related study of hepatitis B virus chronic carrier state in infants from an endemic area (Senegal).

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Isolated antibody to hepatitis B core antigen in human immunodeficiency virus type-1-infected individuals

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevalence of isolated antibody to hepatitis B core antigen in an area endemic for hepatitis B virus infection: implications in hepatitis B vaccination programs

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Susceptibility of chronic symptomless HBsAg carriers to ethanol-induced hepatic damage

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis-B vaccine and hepatitis-B immunoglobulin. Double-blind randomised placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Transmission of hepatitis B virus to multiple patients from a surgeon without evidence of inadequate infection control

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

The infected health care provider

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in health care workers (HCWs): guidelines for prevention of transmission of HBV and HCV from HCW to patients.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Doctor to patient transmission of hepatitis B virus: implications of HBV DNA levels and potential new solutions

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

De novo hepatitis B after liver transplantation from hepatitis B core antibody—Positive donors in an area with high prevalence of anti-HBc positivity in the donor population

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Review article: hepatitis B and liver transplantation

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis B virus genotypes in the United States: results of a nationwide study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B: a longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis B genotypes and the response to interferon therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

A longitudinal follow-up of asymptomatic hepatitis B surface antigen-positive chinese children

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Changes of serum hepatitis B virus DNA and aminotransferase levels during the course of chronic hepatitis B virus infection in children

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection. Incidence, predisposing factors and etiology

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Regional prevalence of hepatitis B, delta, and human immunodeficiency virus infection in southern Africa: a large population survey

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical and histological outcome after hepatitis B e antigen to antibody seroconversion in children with chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

The impact of the hepatitis B mass immunisation campaign on the incidence and risk factors of acute hepatitis B in Italy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Natural history and prognostic factors for chronic hepatitis type B

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP)

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Lamivudine for patients with chronic hepatitis B and advanced liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Genotypes, nt 1858 variants, and geographic origin of hepatitis B virus--large-scale analysis using a new genotyping method

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Precore mutant hepatitis B virus infection and liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Rapid detection of genotypes and mutations in the pre-core promoter and the pre-core region of hepatitis B virus genome: correlation with viral persistence and disease severity

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pre-genome encapsidation signal

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Natural history and prognosis of hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis B e antigen and the risk of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Spontaneous clearance of high-titer serum HBV DNA and risk of hepatocellular carcinoma in a Chinese population

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of concurrent acute infection with hepatitis C virus on acute hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Displacement of hepatitis B virus by hepatitis C virus as the cause of continuing chronic hepatitis.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Fulminant hepatic failure in acute hepatitis C: increased risk in chronic carriers of hepatitis B virus

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Chronic hepatitis D: a vanishing Disease? An Italian multicenter study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep)

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Interactions between human immunodeficiency virus-1, hepatitis delta virus and hepatitis B virus infections in 260 chronic carriers of hepatitis B virus.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS).

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular diagnosis of viral hepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Real time TaqMan PCR detection and quantitation of HBV genotypes A-G with the use of an internal quantitation standard.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Acute exacerbation in chronic type B hepatitis: comparison between HBeAg and antibody-positive patients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiviral drug resistance: clinical consequences and molecular aspects

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Virologic response and resistance to adefovir in patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Evolution of multi-drug resistant hepatitis B virus during sequential therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

PLACEBO-CONTROLLED TRIAL OF RECOMBINANT α2-INTERFERON IN CHINESE HBsAg-CARRIER CHILDREN

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

LONG-TERM FOLLOW-UP IN A RANDOMISED CONTROLLED TRIAL OF RECOMBINANT α2-INTERFERON IN CHINESE PATIENTS WITH CHRONIC HEPATITIS B INFECTION

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon-alpha treatment of chronic hepatitis B in childhood: a consensus advice based on experience in European children

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Lymphoblastoid interferon alfa with or without steroid pretreatment in children with chronic hepatitis B: a multicenter controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized controlled trial of lymphoblastoid interferon-alpha in patients with chronic hepatitis B lacking HBeAg

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alfa-2b treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis type B

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Anti-HBe-positive chronic hepatitis B with HBV-DNA in the serum response to a 6-month course of lymphoblastoid interferon.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term follow-up of chronic hepatitis B patients treated with interferon alfa

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term remission of chronic hepatitis B after alpha-interferon therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

The long-term effect of treatment with interferon-alpha 2a in chronic hepatitis B. The Long-Term Follow-up Investigator Group. The European Study Group on Viral Hepatitis (EUROHEP). Executive Team on Anti-Viral Treatment.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term follow-up of hepatitis B chronic carriers who responded to interferon therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Lamivudine as initial treatment for chronic hepatitis B in the United States

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Four years of lamivudine treatment in Chinese patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical trial of lamivudine in children with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term therapy of chronic hepatitis B with lamivudine.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Response of pre-core mutant chronic hepatitis B infection to lamivudine

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Durability of serologic response after lamivudine treatment of chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Quantitative polymerase chain reaction assay for serum hepatitis B virus DNA as a predictive factor for post-treatment relapse after lamivudine induced hepatitis B e antigen loss or seroconversion

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Determinants for sustained HBeAg response to lamivudine therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical course after stopping lamivudine in chronic hepatitis B patients with lamivudine-resistant mutants

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Histological outcome during long-term lamivudine therapy.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis B

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Entecavir resistance is rare in nucleoside naïve patients with hepatitis B

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Reactivation of viral replication after replacement of tenofovir by adefovir

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Fanconi syndrome and renal failure induced by tenofovir: a first case report

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Thymosin alpha1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized, controlled study of thymosin-alpha1 therapy in patients with anti-HBe, HBV-DNA-positive chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination therapy with interferon-alpha and ribavirin in patients with dual hepatitis B and hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of chronic hepatitis D with interferon alfa-2a

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of peginterferon alpha-2b in chronic hepatitis delta: Relevance of quantitative RT-PCR for follow-up

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Lamivudine for chronic delta hepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Ninety-six-week efficacy of combination therapy with lamivudine and tenofovir in patients coinfected with HIV-1 and wild-type hepatitis B virus

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk of selecting K65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

The use of lamivudine for patients with acute hepatitis B (a series of cases).

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Recombinant interferon‐α therapy for acute hepatitis B: a randomized, double‐blind, placebo‐controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21513

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/HEP.21513

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34002160&oldid=1954838716"